248 related articles for article (PubMed ID: 29782358)
1. Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity.
Chowdhary M; Sen N; Jeans EB; Miller L; Batus M; Gitelis S; Wang D; Abrams RA
Am J Clin Oncol; 2019 Jan; 42(1):1-5. PubMed ID: 29782358
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.
Look Hong NJ; Hornicek FJ; Harmon DC; Choy E; Chen YL; Yoon SS; Nielsen GP; Szymonifka J; Yeap BY; DeLaney TF; Mullen JT
Eur J Cancer; 2013 Mar; 49(4):875-83. PubMed ID: 23092789
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.
Mullen JT; Kobayashi W; Wang JJ; Harmon DC; Choy E; Hornicek FJ; Rosenberg AE; Chen YL; Spiro IJ; DeLaney TF
Cancer; 2012 Aug; 118(15):3758-65. PubMed ID: 22180344
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
DeLaney TF; Spiro IJ; Suit HD; Gebhardt MC; Hornicek FJ; Mankin HJ; Rosenberg AL; Rosenthal DI; Miryousefi F; Ancukiewicz M; Harmon DC
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1117-27. PubMed ID: 12829150
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
Kraybill WG; Harris J; Spiro IJ; Ettinger DS; DeLaney TF; Blum RH; Lucas DR; Harmon DC; Letson GD; Eisenberg B;
J Clin Oncol; 2006 Feb; 24(4):619-25. PubMed ID: 16446334
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas.
Ogura K; Goto T; Imanishi J; Shinoda Y; Okuma T; Tsuda Y; Kobayashi H; Akiyama T; Hirata M; Yamamoto A; Kawano H
Int J Clin Oncol; 2013 Feb; 18(1):170-6. PubMed ID: 22179493
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
[TBL] [Abstract][Full Text] [Related]
8. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant treatment with preoperative radiotherapy for extremity soft tissue sarcomas: long-term results from a single institution in Turkey.
Dincbas FO; Oksuz DC; Yetmen O; Hiz M; Dervisoglu S; Turna H; Kantarci F; Mandel NM; Koca S
Asian Pac J Cancer Prev; 2014; 15(4):1775-81. PubMed ID: 24641408
[TBL] [Abstract][Full Text] [Related]
10. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
[TBL] [Abstract][Full Text] [Related]
11. Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas.
Pennington JD; Eilber FC; Eilber FR; Singh AS; Reed JP; Chmielowski B; Eckardt JJ; Bukata SV; Bernthal NM; Federman N; Nelson SD; Dry SM; Wang PC; Luu M; Selch MT; Steinberg ML; Kalbasi A; Kamrava M
Am J Clin Oncol; 2018 Dec; 41(12):1154-1161. PubMed ID: 29664796
[TBL] [Abstract][Full Text] [Related]
12. Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.
Roeder F; Lehner B; Schmitt T; Kasper B; Egerer G; Sedlaczek O; Grüllich C; Mechtersheimer G; Wuchter P; Hensley FW; Huber PE; Debus J; Bischof M
BMC Cancer; 2014 May; 14():350. PubMed ID: 24885755
[TBL] [Abstract][Full Text] [Related]
13. Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience.
Stubbe F; Agaimy A; Ott O; Lettmaier S; Vassos N; Croner R; Hohenberger W; Fietkau R; Semrau S
Cancer Radiother; 2016 Feb; 20(1):6-13. PubMed ID: 26700874
[TBL] [Abstract][Full Text] [Related]
14. Dana-Farber Cancer Institute studies in advanced sarcoma.
Antman KH; Elias A
Semin Oncol; 1990 Feb; 17(1 Suppl 2):7-15. PubMed ID: 2106162
[TBL] [Abstract][Full Text] [Related]
15. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
16. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
[TBL] [Abstract][Full Text] [Related]
18. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
Mahmoud O; Dosch A; Kwon D; Pitcher JD; Conway S; Benedetto P; Fernandez G; Trent J; Temple HT; Wolfson AH
Am J Clin Oncol; 2016 Oct; 39(5):528-34. PubMed ID: 24879472
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy.
Brandts CH; Schulz C; Willich N; Steffen B; Hardes J; Gosheger G; Winkelmann W; Serve H; Heinecke A; Berdel WE; Thomas M
Cancer Chemother Pharmacol; 2012 Mar; 69(3):613-20. PubMed ID: 21947168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
